Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsOlder adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.
A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.
A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.
Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.
1.
With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.
2.
Mezigdomide Combinations Show Promise in Multiple Myeloma
3.
Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?
4.
Prostate cancer explained: From antigen tests to treatment options
5.
In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.
1.
The Precision Revolution: Bispecific Antibodies and Antibody-Drug Conjugates Reshaping the Oncology Landscape
2.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
3.
What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide
4.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
5.
Octreotide's Efficacy in Reducing Transfusion Requirements in Angiodysplasia Bleeding
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge